Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market

Published: Thursday, March 07, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
20% of overall increase in R&D expenditure in just a year.

Biotech firms eager to push drug candidates through clinical trials prompted an overall increase in R&D expenditure of 20% in just a year, states research and consulting firm GlobalData.

GlobalData’s new report, which compares the competitive position of 15 innovative mid-cap biotech companies on 20 financial metrics, states that the peer group R&D spend for Q3 2012 reached US$746.8m, climbing from US$621.1m in Q3 2011.

“Oncology is the main focus of biotech R&D activities,” says Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics, “which is driving peer group R&D expenses higher.”

Regeneron was the firm with the highest R&D expenditure for Q3 2012, with an outlay of US$158m.

According to the report, Regeneron’s R&D spend has increased steadily each quarter since Q3 2011, when the total stood at US$128m.

“Biotech companies are becoming increasingly more successful at developing innovative therapies,” says Dion. “However, our research has found that the high cost of bringing these therapies to market continues to erode corporate profitability.”

In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditure.

The company’s R&D spending plummeted 28% year-to-year, from US$22.9m in Q3 2011 to US$16.5m in Q3 2012.

The decrease in ViroPharma’s R&D spend was caused by the Food and Drug Administration’s suspension of the company’s clinical trials of its flagship product Cinryze due to safety concerns.

“The FDA put a hold on two of the company’s Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study,” explains Dion. “These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year.”

As defined by a proprietary ratings system based on a number of financial metrics including revenue, sales growth and cost containment, GlobalData identified Regeneron as the peer group benchmark leader in the third quarter, overtaking the Q2 2012 number one, Alexion.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Personalized Screening for Ovarian Cancer
With 60% of women diagnosed with ovarian cancer dying within five years of diagnosis there has been considerable efforts to try to detect the disease at an earlier stage.
Tuesday, June 30, 2015
Promising Malaria and Dengue Vaccines Will Not Defeat Diseases
Although vaccination is a key part of the control of disease GlobalData stress the importance of a multi-dimensional approach.
Friday, May 22, 2015
Pfizer Contemplates $2 Billion Acquisition of Strides’ Agila Unit
As drug makers continue to jostle for market share and deal with declining revenues from their off-patent blockbuster drugs, M&A activity is showing no indication of slowing down in 2013.
Thursday, January 17, 2013
The Fall from Grace of Peregrine Pharmaceuticals
On September 24, 2012, the company announced the discovery of ‘major data discrepancies’ between reported results and patient treatment code assignments.
Wednesday, October 17, 2012
World Water Monitoring Day 2012: Microbes a Major Threat to Potable Water
Non-profit trying to address the issue by increasing access to safe drinking water.
Friday, September 21, 2012
T-DM1 Demonstrates Overall Survival Benefit in Metastatic Breast Cancer
Next target, FDA approval.
Thursday, August 30, 2012
Tofacitinib: Sacrificing Safety for Novelty?
FDA has extended the review period of tofacitinib by three months.
Wednesday, August 22, 2012
Heavyweight Battle: Buyer-Versus-Supplier Showdown in Childhood Vaccines
Federal judge moves forward with meningococcal vaccine antitrust suit against Sanofi.
Tuesday, August 21, 2012
Poor Healthcare Policies and Infrastructure, But India’s Pharma Market Continues to Boom
Country’s pharmaceutical industry continue to expand rapidly in the coming years.
Tuesday, August 21, 2012
The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis
Remsima is the first officially approved biosimilar antibody for RA therapy.
Thursday, August 09, 2012
The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis
Celltrion announces the approval of Remsima (CT-P13), a biosimilar antibody, by the Korean Food and Drug Administration.
Wednesday, August 08, 2012
Lifestyle and Infectious Diseases Encourage IVD Market in Emerging Countries
The market for IVD in the BRIC countries is expected to grow at a CAGR of 16% in 2018.
Friday, May 11, 2012
Dyeing to Paint the Alzheimer’s Brain
Alzheimer’s disease (AD) is characterized by beta-amyloid plaques. Most patients are diagnosed late-stage in the disease or are misdiagnosed with another form of dementia.
Thursday, April 12, 2012
Aplastic Anemia Patients in Need of New Treatment Options
New study explores the failings of current treatment options for aplastic anemia.
Friday, February 24, 2012
Scientific News
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Flinders Ig Nobel Winner Cracks Global Anaesthetic
One of the world’s most in-demand anaesthetics can now be produced on the spot, thanks to the thermos-flask sized device that recently won Flinders University inventor Professor Colin Raston an Ig Nobel prize.
Resurrected Proteins Double Their Natural Activity
Researchers demonstrate method for reviving denatured proteins.
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Messing With The Monsoon
Manmade aerosols can alter rainfall in the world’s most populous region.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Scientists Decode Structure at Root of Muscular Disease
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos